证券代码：688180 证券简称：君实生物 公告编号：临2025-063 上海君实生物医药科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 投资者可于2025年10月22日（星期三）至2025年10月28日（星期二）16:00前登录上证路演中心网站 首页点击"提问预征集"栏目或通过上海君实生物医药科技股份有限公司（以下简称"公司"）邮箱 info@junshipharma.com进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 公司将于2025年10月29日在上海证券交易所网站（www.sse.com.cn）披露公司2025年第三季度报告，为 便于广大投资者更全面深入地了解公司2025年第三季度的经营成果、财务状况，公司计划于2025年10月 29日11：00-12：00召开2025年第三季度业绩说明会，就投资者关心的问题进行交流。 登录新浪财经APP 搜索【信披】查看更多考评等级 （一）投资者可在2025年10月29日（星期三）上午 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於召開2025年第三季度業績說明會的公告》， 僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年10月21日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-063 上海君实生物医药科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 29 日（星期三）11：00-12：00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 22 日（星期三）至 2025 年 10 月 28 日（星期 二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海君 实生物医药科技股份有限公司（以下简称"公司"）邮箱 info@junshipharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 公司将于 2025 年 10 月 29 日在上海证券交易所网站（www.sse.com.cn）披 露公司 2 ...

Group 1 - The core point of the news is that Junshi Biosciences experienced a slight decline in stock price and significant trading activity, with notable financing and margin trading figures indicating high levels of investor engagement [1][2][3] Group 2 - On October 20, Junshi Biosciences' stock fell by 0.34%, with a trading volume of 351 million yuan. The financing buy-in amount was 28.92 million yuan, while the financing repayment was 33.51 million yuan, resulting in a net financing outflow of 4.59 million yuan [1] - As of October 20, the total financing and margin trading balance for Junshi Biosciences was 1.401 billion yuan, with the financing balance at 1.39 billion yuan, accounting for 4.69% of the circulating market value, which is above the 90th percentile of the past year [1] - In terms of margin trading, on October 20, Junshi Biosciences had 3,815 shares repaid and 2,550 shares sold short, with a short selling amount of 98,600 yuan. The remaining short selling volume was 284,500 shares, with a margin balance of 11 million yuan, also above the 90th percentile of the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of June 30, 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] Group 4 - As of June 30, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares from the previous period. The E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [3] - Hong Kong Central Clearing Limited was the tenth largest circulating shareholder, holding 13.1291 million shares, a decrease of 186,650 shares from the previous period [3]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.48% from October 13 to October 17, underperforming the broader market index, the CSI 300, which fell by 2.22% [3][8] - There is a sustained enthusiasm for business development (BD) transactions in innovative drugs, with several companies entering agreements with international pharmaceutical firms [3][12] - The ESMO conference held from October 17 to 21 showcased positive advancements in multiple studies, particularly in immunotherapy and antibody-drug conjugates (ADCs), highlighting the potential of domestic biotech companies [3][11] Market Weekly Review - The pharmaceutical and biotechnology sector saw a weekly decline of 2.48%, with offline pharmacies and traditional Chinese medicine showing slight gains of 0.59% and 0.38%, respectively [8] - Medical research outsourcing, medical devices, and other biological products faced significant declines, with drops of 6.46%, 5.37%, and 3.6% respectively [8][9] - Notable stock performances included Asia-Pacific Pharmaceutical with a rise of 36.7%, while Betta Pharmaceuticals saw a decline of 17.0% [11] Industry News and Key Company Announcements Important Industry Events - On October 18, Kangfang Biologics presented data on a PD-1/VEGF dual antibody in non-small cell lung cancer at the ESMO conference, showing significant improvement in progression-free survival (PFS) [11] - On October 16, Hansa Biopharma announced a licensing agreement with Roche for the global exclusive rights to develop and commercialize HS-20110, with an upfront payment of $80 million [12] - On October 16, Prigen Biologics entered a collaboration with Gilead's Kite Pharma, receiving an upfront payment of $120 million [12][13] Company Announcements - Huayuan Biologics reported a slight decrease in total revenue for the third quarter, amounting to 936 million yuan, a 0.2% year-on-year decline [14] - Shanghai Pharmaceuticals received FDA approval for Doxycycline capsules, with projected sales of approximately $130 million in the U.S. for 2024 [14][16]

Market Overview - The biopharmaceutical sector experienced a decline of 1.51% on October 17, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers included: - Hualan Weishen (301207) with a closing price of 19.49, up 9.80% and a trading volume of 182,600 shares, totaling 349 million yuan [1] - ST Weiming (002581) closed at 7.65, up 4.37% with a trading volume of 125,000 shares, totaling 9.524 million yuan [1] - Major decliners included: - Olin Bio (688319) closed at 22.91, down 6.45% with a trading volume of 68,700 shares, totaling 161 million yuan [2] - Kanhua Bio (300841) closed at 75.29, down 4.08% with a trading volume of 33,800 shares, totaling 260 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 581 million yuan from institutional investors, while retail investors contributed a net inflow of 444 million yuan [2] - The detailed capital flow for selected stocks showed: - Junshi Bio (688180) had a net inflow of 63.85 million yuan from institutional investors, but a net outflow of 61.01 million yuan from retail investors [3] - Hualan Weishen (301207) saw a net inflow of 18.07 million yuan from institutional investors, with a net outflow of 20.09 million yuan from retail investors [3]

Core Viewpoint - Junshi Biosciences (01877) has received FDA approval for its clinical trial application for JS207, a dual-specific antibody targeting PD-1 and VEGF, aimed at treating non-small cell lung cancer patients [1][2]. Group 1 - Junshi Biosciences' stock opened nearly 5% higher and is currently trading at 28.04 HKD with a transaction volume of 6.41 million HKD [1]. - The clinical trial for JS207 is a Phase II/III study comparing it to Nivolumab in patients with resectable, AGA-negative non-small cell lung cancer [1]. - JS207 is a recombinant humanized dual-specific antibody that binds with high affinity to both PD-1 and VEGFA, effectively blocking their interactions and exhibiting properties of both immunotherapy and anti-angiogenic drugs [1]. Group 2 - As of the announcement date, JS207 has been approved to enter Phase II/III clinical research, with additional Phase II studies ongoing in various cancers including non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, and liver cancer [2]. - The ongoing studies are exploring combinations of JS207 with chemotherapy, monoclonal antibodies, and antibody-drug conjugates (ADCs) [2].

Core Viewpoint - Junshi Biosciences (01877) experienced a nearly 5% increase in stock price following the announcement of FDA approval for its clinical trial application for JS207, a dual-specific antibody targeting PD-1 and VEGF for the treatment of non-small cell lung cancer [1][2]. Group 1: Product Development - JS207 is a recombinant humanized dual-specific antibody targeting PD-1 and VEGF, developed by the company for the treatment of advanced malignancies [1]. - The antibody effectively blocks the binding of PD-1 to PD-L1 and PD-L2, as well as the binding of VEGF to its receptors, showcasing both immunotherapy and anti-angiogenesis properties [1]. - The drug aims to improve the tumor microenvironment by inhibiting endothelial cell proliferation and increasing the infiltration of cytotoxic T lymphocytes, thereby enhancing anti-tumor activity [1]. Group 2: Clinical Research - As of the announcement date, JS207 has been approved to enter the Phase II/III clinical research stage, with multiple ongoing Phase II studies exploring its use in various cancers, including non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, and liver cancer [2]. - The ongoing studies are investigating combinations of JS207 with chemotherapy, monoclonal antibodies, and antibody-drug conjugates (ADCs) [2].

Group 1: Apple Inc. - Apple is preparing to launch a MacBook Pro with a touch screen, featuring an OLED display and M6 series chips, expected to be released in late 2026 or early 2027, with a potential price increase of several hundred dollars due to higher component costs [6][7] - Apple CEO Tim Cook met with China's Minister of Commerce Wang Wentao to discuss US-China trade relations and Apple's business development in China, emphasizing the need for stable cooperation between the two countries [3] Group 2: Semiconductor Industry - Chip manufacturer Xilinx plans to increase capital by 1.8 billion yuan to support its 12-inch integrated circuit manufacturing project [7] - TSMC raised its revenue growth forecast for 2025 to the mid-range of 30%, citing stronger-than-expected AI demand, with a projected gross margin of 59% to 61% for Q4 [5] Group 3: Financial Performance - Rongzhi Rixin expects a net profit increase of 871% to 908% year-on-year for the first three quarters of 2025, projecting a profit of 26.4 million to 27.4 million yuan [7] - Shijia Photon reported a 727.74% year-on-year increase in net profit for the first three quarters of 2025, with revenue growth of 113.96% [8]

Core Viewpoint - Junshi Biosciences has received FDA approval for its investigational new drug application for JS207, a bispecific antibody targeting PD-1 and VEGF, aimed at treating resectable non-small cell lung cancer (NSCLC) in a phase 2/3 clinical study [1][3][4] Industry Overview - Lung cancer is the most prevalent and deadly malignant tumor globally, with approximately 2.48 million new cases and 1.82 million deaths reported in 2022 [2] - Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, with 20%-25% being surgically resectable at diagnosis; however, 30%-55% of these patients experience recurrence post-surgery [2] Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company founded in December 2012, focusing on the discovery and commercialization of novel therapies, with over 50 drug candidates in its R&D pipeline [8][9] - The company has five therapeutic focus areas, including cancer, and has received approvals for five products in China and international markets, including toripalimab, China's first domestically produced anti-PD-1 monoclonal antibody [8] Product Details - JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody developed by Junshi Biosciences, currently approved for phase 2/3 clinical studies and being explored in various cancers [5][6] - The drug can bind to PD-1 and VEGFA, blocking their interactions and improving the tumor microenvironment, which enhances anti-tumor activity [6][7] Clinical Study Insights - The phase 2/3 clinical study is an open-label, two-arm, randomized, active-controlled trial comparing JS207 to nivolumab for neoadjuvant treatment in patients with stage II/III, resectable, AGA-negative NSCLC [3][4] - Professor Yilong WU from Guangdong Provincial People's Hospital will lead the study as the principal investigator [3]